首页|缩宫素联合马来酸麦角新碱对高危产妇自然分娩产后出血的作用及凝血因子的影响

缩宫素联合马来酸麦角新碱对高危产妇自然分娩产后出血的作用及凝血因子的影响

扫码查看
目的 研究高危产妇自然分娩后使用缩宫素联合马来酸麦角新碱对产后出血的作用及凝血因子的影响。方法 60 例高危产妇,均行自然分娩,按入院顺序及产妇意愿分为对照组(32 例)和观察组(28 例)。对照组分娩后给予缩宫素治疗,观察组分娩后给予缩宫素联合马来酸麦角新碱治疗。比较两组产后 30 min、2 h、12 h、24 h的出血量,产后 1、3、5 d的宫底高度,产后恶露情况及不良反应发生情况,治疗前后凝血因子[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、纤维蛋白原(FIB)、凝血酶时间(TT)]。结果 观察组产后 30 min、2 h、12 h、24 h的出血量分别为(251。33±7。29)、(298。25±12。38)、(322。30±16。25)、(339。63±23。09)ml,少于对照组的(282。56±10。23)、(345。13±18。09)、(386。31±20。32)、(426。52±29。57)ml(P<0。05)。观察组产后 3、5 d的宫底高度分别为(15。92±2。55)、(13。72±2。31)cm,均低于对照组的(18。13±2。23)、(15。63±2。52)cm(P<0。05)。治疗后,两组APTT、PT、TT均较本组治疗前缩短,FIB较本组治疗前升高,且观察组APTT、PT、TT短于对照组,FIB高于对照组(P<0。05)。观察组血性恶露持续时间(6。16±1。03)d、恶露完全消失时间(5。46±0。75)周均短于对照组的(8。27±1。16)d、(6。33±1。02)周(P<0。05)。两组不良反应总发生率比较无统计学差异(P>0。05)。观察组总有效率 96。43%高于对照组的 78。13%(P<0。05)。结论 高危产妇自然分娩后使用缩宫素联合马来酸麦角新碱对产后出血有明显的预防和治疗作用,可有效改善凝血因子,促进子宫复旧,改善恶露情况,且不良反应少,安全可靠。
The role of oxytocin combined with ergometrine maleate on postpartum hemorrhage after vaginal delivery in high-risk parturients and its influence of coagulation factors
Objective To study the role of oxytocin combined with ergometrine maleate on postpartum hemorrhage after vaginal delivery in high-risk parturient and its influence of coagulation factors.Methods 60 high-risk parturients,all of whom underwent vaginal delivery.They were divided into a control group(32 cases)and an observation group(28 cases)according to admission order and maternal willingness.Patients in the control group were treated with oxytocin,and those in the observation group were treated with oxytocin combined with ergometrine maleate.Both groups were compared in terms of bleeding volume at 30 min,2 h,12 h,and 24 h postpartum,as well as the fundus height at 1 d,3 d,and 5 d postpartum,lochia,and adverse reactions,coagulation factors[activated partial thromboplastin time(APTT),prothrombin time(PT),fibrinogen(FIB),thrombin time(TT)]before and after treatment.Results The postpartum bleeding volume in the observation group were(251.33±7.29),(298.25±12.38),(322.30±16.25)and(339.63±23.09)ml at 30 min,2 h,12 h,and 24 h postpartum,which were less than(282.56±10.23),(345.13±18.09),(386.31±20.32)and(426.52±29.57)ml in the control group(P<0.05).The fundus height of the observation group were(15.92±2.55)and(13.72±2.31)cm at 3 and 5 d postpartum,which were lower than(18.13±2.23)and(15.63±2.52)cm of the control group(P<0.05).After treatment,APTT,PT and TT in both groups were shorter than those before treatment,and FIB was higher than that before treatment;APTT,PT and TT in the observation group were shorter than those in the control group,and FIB was higher than that in the control group(P<0.05).In the observation group,the duration of bloody lochia was(6.16±1.03)d and the time for complete disappearance of lochia was(5.46±0.75)weeks,which were shorter than(8.27±1.16)d and(6.33±1.02)weeks in the control group(P<0.05).There was no statistical difference in the comparison of the total incidence of adverse reactions between the two groups(P>0.05).The total effective rate of 96.43% in the observation group was higher than 78.13% in the control group(P<0.05).Conclusion The use of oxytocin combined with ergometrine maleate after vaginal delivery has a significant preventive and therapeutic effect on postpartum hemorrhage.It can effectively improve coagulation factors,promote uterine involution,and improve lochia,with fewer adverse reactions.It is safe and reliable.

High-risk parturientsVaginal deliveryOxytocinErgometrine maleatePostpartum hemorrhageCoagulation factors

杨春杏、甘成亮、张莹莹

展开 >

519000 珠海市香洲区人民医院妇产科

高危产妇 自然分娩 缩宫素 马来酸麦角新碱 产后出血 凝血因子

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(18)